Thiopurine therapy improves quality of life

March 1, 2010, BioMed Central

Patients with inflammatory bowel diseases (IBDs) such as Crohn's disease or ulcerative colitis do perceive a benefit from thiopurine treatment. A report in the open access journal BMC Gastroenterology has demonstrated improved health-related quality of life in 92 IBD patients.

Guillermo Bastida worked with a team of researchers from La Fe Hospital, Valencia, Spain, to investigate the controversial thiopurine treatment. He said, "The efficacy of thiopurines in the scenarios in which they are prescribed, either to induce or to maintain remission in IBD, is well proven. Their effect on has been a cause for concern however, with some reports suggesting that they can cause patients to perceive their lives as being more difficult while under treatment. However, the available data were scarce, so we carried out this clinical trial to study the problem more closely".

Bastida and his colleagues report that after one year of treatment with thiopurines, quality of life had improved significantly compared with baseline and all the scores were higher than those obtained at six months.

More information: The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients, Guillermo Bastida, Pilar Nos, Mariam Aguas, Marisa Iborra, Vicente Ortiz, Vicente Garrigues and Julio Ponce, BMC Gastroenterology (in press)

Related Stories

Recommended for you

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

New therapeutic gel shows promise against cancerous tumors

February 21, 2018
Scientists at the UNC School of Medicine and NC State have created an injectable gel-like scaffold that can hold combination chemo-immunotherapeutic drugs and deliver them locally to tumors in a sequential manner. The results ...

Kinase inhibitor larotrectinib shows durable anti-tumor abilities

February 21, 2018
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors ...

Five novel genetic changes linked to pancreatic cancer risk

February 21, 2018
In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center and the National Cancer Institute, and collaborators from over 80 other ...

Similarities found in cancer initiation in kidney, liver, stomach, pancreas

February 21, 2018
Recent research at Washington University School of Medicine in St. Louis demonstrated that mature cells in the stomach sometimes revert back to behaving like rapidly dividing stem cells. Now, the researchers have found that ...

Research could change how doctors treat leukemia and other cancers fed by fat

February 21, 2018
Obesity and cancer risk have a mysterious relationship, with obesity increasing the risk for 13 types of cancer. For some cancers—including pediatric cancers—obesity affects survival rates, which are lower for people ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

deatopmg
1 / 5 (1) Mar 01, 2010
Crohn's disease is effectively controlled with low dose naltrexone for a very low cost, instead of expensive patented drugs like thiopurine. THere is some evidence that other IBDs are also controlled by LDN.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.